Post
SNIPR targets antibiotic resistance with CRISPR-based gene therapy trial
The Danish CRISPR biotech SNIPR BIOME has released the first glimpse at the safety profile for SNIPR001, a gene therapy …
FDA proposes new model for easy-to-understand prescription guides
The US Food and Drug Administration (FDA) has proposed a new model for prescription medication guides for brand name and …
Anocca raises over $36 million for cancer cell therapy studies
Anocca has raised SEK 400 million ($36.7 million) in an equity financing round that will be used to move the …
After US approval, Amylyx faces regulatory hurdle in Europe for ALS treatment
Following a rocky and somewhat controversial road to securing a US Food and Drug Administration (FDA) approval, Amylyx’s amyotrophic lateral …
BBT-401 by Bridge Biotherapeutics for Ulcerative Colitis: Likelihood of Approval
BBT-401 is under clinical development by Bridge Biotherapeutics and currently in Phase II for Ulcerative Colitis. According to GlobalData, Phase …
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Sentiment towards Brexit has worsened three years after UK left EU
More than half (54%) of the surveyed healthcare industry professionals indicated that their sentiment towards Brexit had become more negative. …
Janssen submits NDA to FDA for PAH combination therapy
The Janssen Pharmaceutical Companies of Johnson & Johnson has submitted a new drug application (NDA) for its investigational single-tablet combination …
Stealth and Pharmanovia partner for commercialisation of elamipretide
Stealth BioTherapeutics has made an exclusive licensing agreement with Pharmanovia for the commercialisation of its elamipretide to treat Barth syndrome. Pharmanovia …
Betta to commercialise C4 Therapeutics’ CFT8919 in greater China
C4 Therapeutics has entered an exclusive licensing agreement with Betta Pharmaceuticals to develop and commercialise CFT8919 across the greater China …
XtalPi announces $250m AI drug discovery collaboration with Eli Lilly
XtalPi has made a partnership deal with US-based Eli Lilly to leverage artificial intelligence (AI) for drug discovery. XtalPi will receive …
FDA accepts Bristol Myers Squibb’s repotrectinib NDA for review
The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s new drug application (NDA) for repotrectinib for priority …
University of Sydney will use AI to boost cancer drug research
The University of Sydney and Australian company Pharos Therapeutics have reached an agreement to leverage artificial intelligence (AI) to progress …
Early signals suggest oral SERD’s potential for more breast cancer patients
The Menarini Group today has announced exploratory results from its EMERALD clinical study that suggest its recently approved oral selective …
US companies drive 2023 drug launches positioned for blockbuster success by 2028
According to GlobalData's Looking Ahead to 2023 – the Future of Pharma report, five drugs set for approval in 2023 …
AION Labs and BioMed X launch sixth challenge for AI-driven drug discovery
Last week, artificial intelligence (AI) innovator AION Labs called for applications for its latest AI-powered startup. In partnership with BioMed …